242 related articles for article (PubMed ID: 32418256)
21. Treatment patterns and clinical outcomes in high-risk newly diagnosed multiple myeloma patients carrying the 17p deletion: An observational multi-center retrospective study.
Cohen YC; Saranga A; Gatt ME; Lavi N; Ganzel C; Magen H; Avivi I; Tadmor T; Suriu C; Jarchowsky Dolberg O; Papushado A; Trestman S; Ram R
Am J Hematol; 2018 Jun; 93(6):810-815. PubMed ID: 29603773
[TBL] [Abstract][Full Text] [Related]
22. Treatment patterns and outcomes of Stage IIIB/IIIC melanoma in France, Germany and the UK: A retrospective and prospective observational study (MELABIS).
Harries M; Mohr P; Grange F; Ehness R; Benjamin L; Siakpere O; Barth J; Stapelkamp C; Pfersch S; McLeod L; Wolowacz S; Kaye JA; Kontoudis I
Int J Clin Pract; 2017 May; 71(5):. PubMed ID: 28508460
[TBL] [Abstract][Full Text] [Related]
23. Multiple myeloma treatment patterns and clinical outcomes in the Latin America Haemato-Oncology (HOLA) Observational Study, 2008-2016.
de Moraes Hungria VT; Martínez-Baños DM; Peñafiel CR; Miguel CE; Vela-Ojeda J; Remaggi G; Duarte FB; Cao C; Cugliari MS; Santos T; Machnicki G; Fernandez M; Grings M; Ammann EM; Lin JH; Chen YW; Wong YN; Barreyro P
Br J Haematol; 2020 Feb; 188(3):383-393. PubMed ID: 31392724
[TBL] [Abstract][Full Text] [Related]
24. Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival.
Katodritou E; Kyrtsonis MC; Delimpasi S; Kyriakou D; Symeonidis A; Spanoudakis E; Vasilopoulos G; Anagnostopoulos A; Kioumi A; Zikos P; Aktypi A; Briasoulis E; Megalakaki A; Repousis P; Adamopoulos I; Gogos D; Kotsopoulou M; Pappa V; Papadaki E; Fotiou D; Nikolaou E; Giannopoulou E; Hatzimichael E; Giannakoulas N; Douka V; Kokoviadou K; Timotheatou D; Terpos E
Ann Hematol; 2018 Sep; 97(9):1671-1682. PubMed ID: 29756171
[TBL] [Abstract][Full Text] [Related]
25. Multiple myeloma: Every year a new standard?
Rajkumar SV
Hematol Oncol; 2019 Jun; 37 Suppl 1(Suppl 1):62-65. PubMed ID: 31187526
[TBL] [Abstract][Full Text] [Related]
26. Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study.
Cohen YC; Magen H; Lavi N; Gatt ME; Chubar E; Horowitz N; Kreiniz N; Tadmor T; Trestman S; Vitkon R; Rouvio O; Shvetz O; Shaulov A; Ziv-Baran T; Avivi I
Ann Hematol; 2020 Jun; 99(6):1273-1281. PubMed ID: 32193630
[TBL] [Abstract][Full Text] [Related]
27. Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG Research Project.
Usmani SZ; Hoering A; Cavo M; Miguel JS; Goldschimdt H; Hajek R; Turesson I; Lahuerta JJ; Attal M; Barlogie B; Lee JH; Kumar S; Lenhoff S; Morgan G; Rajkumar SV; Durie BGM; Moreau P
Blood Cancer J; 2018 Nov; 8(12):123. PubMed ID: 30470751
[TBL] [Abstract][Full Text] [Related]
28. Productivity losses in patients with newly diagnosed multiple myeloma following stem cell transplantation and the impact of maintenance therapy.
Jackson G; Galinsky J; Alderson DEC; D'Souza VK; Buchanan V; Dhanasiri S; Walker S
Eur J Haematol; 2019 Oct; 103(4):393-401. PubMed ID: 31325331
[TBL] [Abstract][Full Text] [Related]
29. [Prognostic factors in newly diagnosed multiple myeloma patients with 1q21 amplification/gain treated with bortezomib-based regimens followed by autologous hematopoietic stem cell transplantation].
Huang WY; Zou DH; Liu W; An G; Xu Y; Sui WW; Deng SH; Li CW; Liu H; Li J; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2018 Jun; 39(6):496-500. PubMed ID: 30032568
[No Abstract] [Full Text] [Related]
30. Changes in treatment landscape of relapsed or refractory multiple myeloma and their association with mortality: Insights from German claims database.
Scheid C; Blau IW; Sellner L; Ratsch BA; Basic E
Eur J Haematol; 2021 Feb; 106(2):148-157. PubMed ID: 32989806
[TBL] [Abstract][Full Text] [Related]
31. Clinical significance of granule-containing myeloma cells in patients with newly diagnosed multiple myeloma.
Suzuki K; Yano S; Nishiwaki K; Sano K; Shimada T; Yahagi Y; Ogasawara Y; Sugiyama K; Takahara S; Saito T; Kasama K; Minami J; Yokoyama H; Kamiyama Y; Katsube A; Masuoka H; Katori M; Machishima T; Ouchi A; Dobashi N; Kaito K; Usui N; Aiba K
Cancer Med; 2016 Nov; 5(11):3051-3058. PubMed ID: 27734595
[TBL] [Abstract][Full Text] [Related]
32. Patterns of total cost and economic consequences of progression for patients with newly diagnosed multiple myeloma.
Arikian SR; Milentijevic D; Binder G; Gibson CJ; Hu XH; Nagarwala Y; Hussein M; Corvino FA; Surinach A; Usmani SZ
Curr Med Res Opin; 2015 Jun; 31(6):1105-15. PubMed ID: 25785551
[TBL] [Abstract][Full Text] [Related]
33. Real-world treatment patterns for patients with newly diagnosed multiple myeloma in Alberta, Canada.
Jimenez-Zepeda VH; Chen G; Shaw E; Farris MS; Cowling T; Tay J
Leuk Lymphoma; 2022 Nov; 63(11):2557-2564. PubMed ID: 35793400
[TBL] [Abstract][Full Text] [Related]
34. Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.
Korde N; Roschewski M; Zingone A; Kwok M; Manasanch EE; Bhutani M; Tageja N; Kazandjian D; Mailankody S; Wu P; Morrison C; Costello R; Zhang Y; Burton D; Mulquin M; Zuchlinski D; Lamping L; Carpenter A; Wall Y; Carter G; Cunningham SC; Gounden V; Sissung TM; Peer C; Maric I; Calvo KR; Braylan R; Yuan C; Stetler-Stevenson M; Arthur DC; Kong KA; Weng L; Faham M; Lindenberg L; Kurdziel K; Choyke P; Steinberg SM; Figg W; Landgren O
JAMA Oncol; 2015 Sep; 1(6):746-54. PubMed ID: 26181891
[TBL] [Abstract][Full Text] [Related]
35. Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma.
Martinez-Lopez J; Wong SW; Shah N; Bahri N; Zhou K; Sheng Y; Huang CY; Martin T; Wolf J
Blood Adv; 2020 Jul; 4(14):3295-3301. PubMed ID: 32706892
[TBL] [Abstract][Full Text] [Related]
36. The EASEMENT study: A multicentre, observational, cross-sectional study to evaluate patient preferences, treatment satisfaction, quality of life, and healthcare resource use in patients with multiple myeloma receiving injectable-containing or fully oral therapies.
Ayto R; Annibali O; Biedermann P; Roset M; Sánchez E; Kotb R
Eur J Haematol; 2024 Jun; 112(6):889-899. PubMed ID: 38389468
[TBL] [Abstract][Full Text] [Related]
37. Investigation of a gene signature to predict response to immunomodulatory derivatives for patients with multiple myeloma: an exploratory, retrospective study using microarray datasets from prospective clinical trials.
Bhutani M; Zhang Q; Friend R; Voorhees PM; Druhan LJ; Barlogie B; Sonneveld P; Morgan GJ; Symanowski JT; Avalos BR; Copelan EA; Usmani SZ
Lancet Haematol; 2017 Sep; 4(9):e443-e451. PubMed ID: 28863804
[TBL] [Abstract][Full Text] [Related]
38. [Clinical characteristics and outcomes of patients newly diagnosed with multiple myeloma with extramedullary disease].
Wang J; Zhang LN; Shi QL; Qu XY; Chen LJ; Li JY; Zhang R
Zhonghua Xue Ye Xue Za Zhi; 2020 Oct; 41(10):822-828. PubMed ID: 33190439
[No Abstract] [Full Text] [Related]
39. How to treat multiple myeloma: thoughts on a multicentre survey in Germany.
Bladé J; Rosiñol L; Cibeira MT; de Larrea CF
Onkologie; 2010; 33(11):577-8. PubMed ID: 20975302
[No Abstract] [Full Text] [Related]
40. Patient Characteristics and Outcomes of Relapsed/Refractory Multiple Myeloma in Patients Treated with Proteasome Inhibitors in Germany.
Steinmetz HT; Singh M; Lebioda A; Gonzalez-McQuire S; Rieth A; Schoehl M; Poenisch W
Oncol Res Treat; 2020; 43(9):449-459. PubMed ID: 32694243
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
